What ChondroFiller does in the hip joint

When ChondroFiller is injected into the hip joint under ultrasound guidance, it arrives as a viscous liquid that gels in place within the cartilage defect, conforming to the shape of the lesion rather than dispersing through the joint fluid. That gelling behaviour matters: instead of washing away, the collagen matrix stays put and creates a physical scaffold that the body can work with.

The mechanism is what specialists call acellular matrix-induced chondrogenesis — which simply means the scaffold itself contains no cells, but is designed to attract the patient's own progenitor cells from the surrounding synovium and subchondral bone into the defect. As those cells migrate in and mature, they progressively replace the resorbing collagen with repair tissue. The scaffold itself breaks down over roughly six to twenty-four months, but the biological process it initiates continues beyond that point.

The primary hip target is a focal, full-thickness cartilage lesion — typically a Grade III or IV defect on the acetabular surface or femoral head, often associated with femoroacetabular impingement (FAI). These are the isolated lesions where healthy surrounding cartilage can support the repair process.

This is fundamentally different from hyaluronic acid viscosupplementation. Hyaluronic acid temporarily improves joint lubrication and manages symptoms; it does not provide a structural scaffold or promote endogenous tissue repair. ChondroFiller, by contrast, is a CE-marked Class III medical device targeting biological regeneration of the defect itself, delivered as a straightforward outpatient injection.

Which hip patients the evidence supports

The five-year results from the Mazek 2021 cohort did not emerge from a general hip-pain population. The 26 adults enrolled carried focal acetabular cartilage lesions exceeding 2 cm² associated with femoroacetabular impingement — and crucially, their underlying joints were graded Tönnis 0 or 1, meaning minimal to no pre-existing osteoarthritis. That context is where the 17-of-21 good-or-excellent finding sits.

Tönnis grading is a radiological scale running from 0 (normal joint) to 3 (severe osteoarthritis). The same cohort made the negative predictor explicit: patients with Tönnis grade 2 or 3 disease had consistently poor outcomes. The scaffold depends on healthy surrounding cartilage to support cell migration and defect integration; in an already-degenerate joint, that biological environment is compromised.

Advanced hip osteoarthritis therefore falls outside the primary evidence base for ChondroFiller as a regenerative scaffold. Some patients with more diffuse joint wear may receive ChondroFiller as an injectable mechanical cushion rather than for structural regeneration — a clinically distinct role operating under different expectations and not supported by the same five-year outcome data.

For anyone wondering whether the evidence applies to their hip, MRI is the practical starting point. It establishes defect size, location, and surrounding joint quality — the three variables that most directly determine whether published outcomes are likely to be relevant to an individual joint.

Harris Hip Score improvements in the published cohort

Across hip cohorts followed for three to five years — with the Mazek 2021 prospective series as the backbone dataset — the mean modified Harris Hip Score (mHHS) improvement following ChondroFiller treatment is approximately +33 points, drawn from a synthesis of available clinical evidence rather than a single dedicated five-year measurement. That framing matters: the figure is a cohort synthesis, not an isolated endpoint, and the Mazek series reported outcomes at years three, four, and five consecutively rather than as a single final snapshot.

The Harris Hip Score runs from 0 to 100 and captures pain severity, walking capacity, stair-climbing ability, and hip range of motion. A gain of +33 points substantially exceeds the established minimal clinically important difference (MCID) — roughly the threshold below which patients cannot reliably detect a functional change in daily life. In concrete terms, a patient entering treatment with a score around 50, carrying significant restriction and pain on most activities, who reaches 83 at follow-up has typically moved from struggling with ordinary walking or managing stairs with difficulty, to functioning close to normally at home and outside.

The Mazek 2021 cohort — 26 adults with FAI-related acetabular defects, of whom 21 remained evaluable at long-term follow-up — provides the primary hip-specific evidence behind this figure. No larger randomised controlled trial in the hip has been completed.

One interpretive note: the HHS carries a recognised ceiling effect. Patients who begin with a high baseline score may show a numerically modest change even with genuine improvement, which is why absolute follow-up score and baseline must be read together rather than relying on the change figure alone.

What MOCART MRI scans show about cartilage repair in the hip

Symptom scores tell clinicians how a patient feels; MRI can show whether repair tissue has actually formed inside the defect. The MOCART 2.0 scoring system — developed by Schreiner et al. in 2019 and scaled from 0 to 100 — provides that structural account by grading five MRI variables: fill volume, repair tissue integration with surrounding native cartilage, surface contour, signal intensity, and subchondral bone changes including oedema and cyst formation. A higher MOCART score indicates more complete, better-integrated repair tissue.

In the Mazek 2021 hip cohort, cartilage repair was assessed on MRI at multiple intervals. At years three, four, and five consecutively, 17 of the 21 evaluable patients — approximately 81% — achieved good or excellent MRI results, confirming that structural improvement was being maintained rather than gradually deteriorating over the mid-term follow-up period.

The maturation trajectory is as informative as the endpoint figure. Drawing on ChondroFiller's broader evidence programme — which includes knee cohorts as well as hip cases — MOCART scores typically begin around 65 at four weeks post-treatment, reflecting early scaffold filling rather than consolidated repair tissue. By twelve months, scores have climbed past 80, and the published range across one-year assessments sits between 70 and 87. That ascending curve matters clinically: it confirms that repair tissue integration continues progressively through the first year rather than reaching a ceiling at the initial follow-up visit.

One caveat is worth stating clearly. The precise MOCART score trajectory cited above is drawn primarily from knee cohorts within the same device evidence programme; the hip-specific Mazek series reported MRI outcomes as categorical good/excellent ratings rather than as MOCART numerical values. The 17/21 hip finding remains the most direct structural evidence in the hip.

How long the benefit lasts and what influences durability

The paradox at the heart of ChondroFiller's durability story is that the scaffold itself does not last. Type I collagen breaks down within six to twenty-four months of placement — yet clinical benefit is reported to persist for one to five years or longer in mid-term evaluations. The explanation lies in what the scaffold does during its working life: it acts as a temporary matrix that recruits the patient's own progenitor cells into the defect, which then produce repair tissue that remains after the collagen has degraded.

That mechanism translates into measurable mid-term durability. Across knee, hip, and small-joint cohorts followed for three to five years at multiple independent centres, approximately 70–85% of patients maintain symptom relief above the MCID threshold — a pooled approximation from several programmes rather than a figure from any single trial. In the Mazek 2021 hip cohort specifically, good or excellent MRI results were recorded consecutively at years three, four, and five, confirming that structural benefit was not a one-year peak that subsequently faded.

One practical note on the early post-injection period: a 2024 in-vitro biomechanical study found that ChondroFiller in its initial state did not protect opposing cartilage surfaces from load-induced damage, attributed to early mechanical instability of the gel. Clinical protocols already account for this by delaying full weight-bearing until stable defect filling is confirmed.

The comparison with microfracture is worth a brief note, because it addresses the question of why a patient might choose this pathway over the current arthroscopic standard for small hip chondral lesions. Microfracture produces fibrocartilaginous repair tissue rather than a hyaline-type regenerate, and published series show its clinical benefit is variable beyond two to three years. ChondroFiller targets a more durable biological outcome through a single outpatient injection stage, and the five-year hip data currently available support that durability advantage — albeit from cohorts too small to allow definitive head-to-head conclusions.

Reading the evidence honestly: what we know and what is still missing

The central evidence gap is straightforward to state: no randomised controlled trial has compared ChondroFiller directly against microfracture or a sham procedure in a hip-specific patient population. A multi-centre RCT in patients with FAI and focal acetabular defects, using five-year patient-reported outcomes as the primary endpoint, would substantially narrow the confidence interval around findings published to date. That study does not yet exist, and the published cohort literature acknowledges as much explicitly.

What the existing evidence does establish is narrower, but still clinically useful. The Mazek 2021 series is a prospective study — with structured long-term follow-up, standardised MRI evaluation at multiple timepoints, and transparent reporting of adverse outcomes including two conversions to total hip replacement during follow-up. It is not an RCT, but it is not anecdote either. Prospective enrolment, pre-specified endpoints, and honest disclosure of those who fared poorly are precisely the features that give a cohort study genuine evidential weight despite its scale.

For a patient whose hip fits the evidence profile — a focal, contained defect with preserved surrounding joint health and Tönnis grade 0–1 — the available data are internally consistent and the benefit signal persists across three consecutive annual assessments out to five years, replicated across independent clinical settings. For a patient with more advanced hip joint degeneration, the same published data offer no comparable case for treatment. That distinction — telling clinicians and patients equally clearly where the evidence applies and where it does not — is what a well-conducted, honestly reported prospective study is supposed to deliver.

1. [1] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
2. [2] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: a biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z